FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3147389511> ?p ?o ?g. }

• W3147389511 endingPage "753" @default.
• W3147389511 startingPage "753" @default.
• W3147389511 abstract "The assessment of new antithrombotic agents with a favorable safety profile is clinically relevant.To test the efficacy and safety of revacept, a novel, lesion-directed antithrombotic drug, acting as a competitive antagonist to platelet glycoprotein VI.A phase 2 randomized clinical trial; patients were enrolled from 9 centers in Germany from November 20, 2017, to February 27, 2020; follow-up ended on March 27, 2020. The study included patients with stable ischemic heart disease (SIHD) undergoing elective percutaneous coronary intervention (PCI).Single intravenous infusion of revacept, 160 mg, revacept, 80 mg, or placebo prior to the start of PCI on top of standard antithrombotic therapy.The primary end point was the composite of death or myocardial injury, defined as an increase in high-sensitivity cardiac troponin to at least 5 times the upper limit of normal within 48 hours from randomization. The safety end point was bleeding type 2 to 5 according to the Bleeding Academic Research Consortium criteria at 30 days.Of 334 participants (median age, 67.4 years; interquartile range, 60-75.1 years; 253 men [75.7%]; and 330 White participants [98.8%]), 120 were allocated to receive the 160-mg dose of revacept, 121 were allocated to receive the 80-mg dose, and 93 received placebo. The primary end point showed no significant differences between the revacept and placebo groups: 24.4%, 25.0%, and 23.3% in the revacept, 160 mg, revacept, 80 mg, and placebo groups, respectively (P = .98). The high dose of revacept was associated with a small but significant reduction of high-concentration collagen-induced platelet aggregation, with a median 26.5 AU × min (interquartile range, 0.5-62.2 AU × min) in the revacept, 160 mg, group; 43.5 AU × min (interquartile range, 22.8-99.5 AU × min) in the revacept, 80 mg, group; and 41.0 AU × min (interquartile range, 31.2-101.0 AU × min) in the placebo group (P = .02), while adenosine 5'-diphosphate-induced aggregation was not affected. Revacept did not increase Bleeding Academic Research Consortium type 2 or higher bleeding at 30 days compared with placebo: 5.0%, 5.9%, and 8.6% in the revacept, 160 mg, revacept, 80 mg, and placebo groups, respectively (P = .36).Revacept did not reduce myocardial injury in patients with stable ischemic heart disease undergoing percutaneous coronary intervention. There were few bleeding events and no significant differences between treatment arms.ClinicalTrials.gov Identifier: NCT03312855." @default.
• W3147389511 created "2021-04-13" @default.
• W3147389511 creator A5001441700 @default.
• W3147389511 creator A5005924135 @default.
• W3147389511 creator A5006952690 @default.
• W3147389511 creator A5007093669 @default.
• W3147389511 creator A5009905903 @default.
• W3147389511 creator A5015044428 @default.
• W3147389511 creator A5015669756 @default.
• W3147389511 creator A5022942959 @default.
• W3147389511 creator A5023286054 @default.
• W3147389511 creator A5027192232 @default.
• W3147389511 creator A5035254382 @default.
• W3147389511 creator A5039515279 @default.
• W3147389511 creator A5040237255 @default.
• W3147389511 creator A5042014267 @default.
• W3147389511 creator A5045000025 @default.
• W3147389511 creator A5049666532 @default.
• W3147389511 creator A5061907666 @default.
• W3147389511 creator A5067546942 @default.
• W3147389511 creator A5072737089 @default.
• W3147389511 creator A5077502588 @default.
• W3147389511 creator A5078073832 @default.
• W3147389511 creator A5079002169 @default.
• W3147389511 creator A5080753934 @default.
• W3147389511 creator A5086489731 @default.
• W3147389511 creator A5088608614 @default.
• W3147389511 creator A5091776005 @default.
• W3147389511 date "2021-07-01" @default.
• W3147389511 modified "2023-10-13" @default.
• W3147389511 title "Efficacy and Safety of Revacept, a Novel Lesion-Directed Competitive Antagonist to Platelet Glycoprotein VI, in Patients Undergoing Elective Percutaneous Coronary Intervention for Stable Ischemic Heart Disease" @default.
• W3147389511 cites W1421247184 @default.
• W3147389511 cites W1517636809 @default.
• W3147389511 cites W1840021307 @default.
• W3147389511 cites W1972832497 @default.
• W3147389511 cites W1989197319 @default.
• W3147389511 cites W1990906644 @default.
• W3147389511 cites W2018383335 @default.
• W3147389511 cites W2029479133 @default.
• W3147389511 cites W2032566195 @default.
• W3147389511 cites W2057372364 @default.
• W3147389511 cites W2087150869 @default.
• W3147389511 cites W2115671168 @default.
• W3147389511 cites W2122779695 @default.
• W3147389511 cites W2144829782 @default.
• W3147389511 cites W2149721689 @default.
• W3147389511 cites W2158745909 @default.
• W3147389511 cites W2165122118 @default.
• W3147389511 cites W2212977094 @default.
• W3147389511 cites W2403373357 @default.
• W3147389511 cites W2752033985 @default.
• W3147389511 cites W2782280176 @default.
• W3147389511 cites W2808359328 @default.
• W3147389511 cites W2902635828 @default.
• W3147389511 cites W2916912835 @default.
• W3147389511 cites W2940034580 @default.
• W3147389511 cites W2951424940 @default.
• W3147389511 cites W2951807550 @default.
• W3147389511 cites W2976884304 @default.
• W3147389511 cites W2979988248 @default.
• W3147389511 cites W2980596005 @default.
• W3147389511 cites W3042854765 @default.
• W3147389511 cites W4234973553 @default.
• W3147389511 cites W4247546790 @default.
• W3147389511 cites W4256195665 @default.
• W3147389511 cites W4293577771 @default.
• W3147389511 doi "https://doi.org/10.1001/jamacardio.2021.0475" @default.
• W3147389511 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/8014195" @default.
• W3147389511 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33787834" @default.
• W3147389511 hasPublicationYear "2021" @default.
• W3147389511 type Work @default.
• W3147389511 sameAs 3147389511 @default.
• W3147389511 citedByCount "33" @default.
• W3147389511 countsByYear W31473895112021 @default.
• W3147389511 countsByYear W31473895112022 @default.
• W3147389511 countsByYear W31473895112023 @default.
• W3147389511 crossrefType "journal-article" @default.
• W3147389511 hasAuthorship W3147389511A5001441700 @default.
• W3147389511 hasAuthorship W3147389511A5005924135 @default.
• W3147389511 hasAuthorship W3147389511A5006952690 @default.
• W3147389511 hasAuthorship W3147389511A5007093669 @default.
• W3147389511 hasAuthorship W3147389511A5009905903 @default.
• W3147389511 hasAuthorship W3147389511A5015044428 @default.
• W3147389511 hasAuthorship W3147389511A5015669756 @default.
• W3147389511 hasAuthorship W3147389511A5022942959 @default.
• W3147389511 hasAuthorship W3147389511A5023286054 @default.
• W3147389511 hasAuthorship W3147389511A5027192232 @default.
• W3147389511 hasAuthorship W3147389511A5035254382 @default.
• W3147389511 hasAuthorship W3147389511A5039515279 @default.
• W3147389511 hasAuthorship W3147389511A5040237255 @default.
• W3147389511 hasAuthorship W3147389511A5042014267 @default.
• W3147389511 hasAuthorship W3147389511A5045000025 @default.
• W3147389511 hasAuthorship W3147389511A5049666532 @default.
• W3147389511 hasAuthorship W3147389511A5061907666 @default.
• W3147389511 hasAuthorship W3147389511A5067546942 @default.
• W3147389511 hasAuthorship W3147389511A5072737089 @default.
• W3147389511 hasAuthorship W3147389511A5077502588 @default.
• W3147389511 hasAuthorship W3147389511A5078073832 @default.

• next